Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Streptococcus pyogenes vaccine
- Development stage
- Preclinical
- Lead developer
- VaxForm
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous, Intradermal, Intranasal, Oral, Dermal
01
Overview
VaxForm's Streptococcus pyogenes vaccine is a recombinant fusion protein vaccine currently in preclinical development for the prevention of Group A Streptococcus (GAS) infections, including pharyngitis (strep throat) and rheumatic fever. The vaccine candidate is a fusion protein consisting of two major virulence factors: Streptococcal pyrogenic exotoxin A (SpeA) and Streptococcal pyrogenic exotoxin B (SpeB). By targeting these exotoxins, the vaccine aims to elicit a protective immune response and neutralize the toxins responsible for the severe manifestations of GAS infections. While VaxForm generally focuses on oral vaccine formulations using its QYNDR platform, the specific route of administration for this candidate has not been explicitly confirmed, though it has undergone preclinical safety and immunogenicity testing in rabbit models.
- Other names
- SpeA-SpeB fusion protein vaccineVaxForm Group A Streptococcus vaccineGroup A Streptococcus vaccine
02
Targets
SpeA (Streptococcal pyrogenic exotoxin A)SCP (Streptococcal C5a peptidase)
Beyond the preview
Go deeper on Streptococcus pyogenes vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Streptococcus pyogenes vaccine.